Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion
- PMID: 12711218
- DOI: 10.1016/S0168-9525(03)00081-7
Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion
Abstract
Genetic analysis of hypertrophic cardiomyopathy (HCM), a mendelian form of cardiac hypertrophy, indicates that the primary defect is in sarcomeric function. However, the initial proposal that depressed myocardial contraction leads to a 'compensatory' hypertrophy has proven inconsistent with laboratory and clinical evidence. Drawing on observations of mutant contractile protein function, together with mouse models and clinical studies, we propose that sarcomeric HCM mutations lead to inefficient ATP utilization. The suggestion that energy depletion underlies HCM is supported by the HCM-like phenotype found with mutations in a variety of metabolic genes. A central role for compromised energetics would also help explain the unresolved clinical observations of delayed onset and asymmetrical hypertrophy in HCM, and would have implications for therapy in HCM and, potentially, in more-common forms of cardiac hypertrophy and failure.
Similar articles
-
Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.J Am Coll Cardiol. 2003 May 21;41(10):1776-82. doi: 10.1016/s0735-1097(02)03009-7. J Am Coll Cardiol. 2003. PMID: 12767664
-
Familial hypertrophic cardiomyopathy: a paradigm of the cardiac hypertrophic response to injury.Ann Med. 1998 Aug;30 Suppl 1:24-32. Ann Med. 1998. PMID: 9800880 Review.
-
Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.J Am Coll Cardiol. 2004 Dec 21;44(12):2315-25. doi: 10.1016/j.jacc.2004.05.088. J Am Coll Cardiol. 2004. PMID: 15607392
-
Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging.Heart. 2009 Mar;95(3):228-33. doi: 10.1136/hrt.2008.142562. Epub 2008 Aug 15. Heart. 2009. PMID: 18708417
-
Mechanical and energetic consequences of HCM-causing mutations.J Cardiovasc Transl Res. 2009 Dec;2(4):441-51. doi: 10.1007/s12265-009-9131-8. Epub 2009 Oct 9. J Cardiovasc Transl Res. 2009. PMID: 20560002 Review.
Cited by
-
Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.Circ Res. 2012 Jul 20;111(3):375-85. doi: 10.1161/CIRCRESAHA.110.223842. Circ Res. 2012. PMID: 22821910 Free PMC article. Review.
-
Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling.Stem Cell Res Ther. 2022 Jul 23;13(1):332. doi: 10.1186/s13287-022-03021-9. Stem Cell Res Ther. 2022. PMID: 35870954 Free PMC article. Review.
-
Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.Stem Cell Reports. 2018 Mar 13;10(3):808-821. doi: 10.1016/j.stemcr.2018.01.013. Epub 2018 Feb 15. Stem Cell Reports. 2018. PMID: 29456182 Free PMC article.
-
Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives.J Clin Med. 2023 Sep 1;12(17):5710. doi: 10.3390/jcm12175710. J Clin Med. 2023. PMID: 37685777 Free PMC article. Review.
-
Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy.Heart Fail Rev. 2017 Nov;22(6):879-888. doi: 10.1007/s10741-017-9648-x. Heart Fail Rev. 2017. PMID: 28856513 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources